Results from an open-label phase II trial showing that crizanlizumab is well tolerated in adolescent patients (aged 12 to <18 years) with SCD and was associated with a reduction in the rate of veno-occlusive crises.
Contact Clinical Care Options
For customer support please email: customersupport@cealliance.com
Mailing Address Clinical Care Options, LLC 12001 Sunrise Valley Drive Suite 300 Reston, VA 20191
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.
Continue